In this slide contains Quality-by-Design in Pharmaceutical Development.
Presented by: T. MOUSAMI BHAVASAR (Department of pharmaceutics). RIPER, anantapur
Biopharmaceutic considerations in drug product design and In Vitro Drug Produ...PRAJAKTASAWANT33
Introduction, biopharmaceutic factors affecting drug bioavailability, rate–limiting steps in drug absorption, physicochemical nature of the drug formulation factors affecting drug product performance
In this slide contains Quality-by-Design in Pharmaceutical Development.
Presented by: T. MOUSAMI BHAVASAR (Department of pharmaceutics). RIPER, anantapur
Biopharmaceutic considerations in drug product design and In Vitro Drug Produ...PRAJAKTASAWANT33
Introduction, biopharmaceutic factors affecting drug bioavailability, rate–limiting steps in drug absorption, physicochemical nature of the drug formulation factors affecting drug product performance
In this presentation I have mentioned whatever the possible relevant content/guidelines require for biowaiver application.
Citation Is done at the end of slide.
Content is up to date & true to my belief.
Thanks & Best Regards.
Anurag Pandey
B.Pharm (FACULTY OF PHARMACY, INVERTIS UNIVERSITY)
M.Pharm (INSTITUTE OF PHARMACY, NIRMA UNIVERSITY)
Email :- anurag.dmk05@gmail.com
The release of the drug substance from the drug product leading to the bioavailability of the drug substance. The assessment of drug product performance is imp. Since bioavailability is related both to the pharmacodynamic responses and the adverse events. The performance tests relate the quality of a drug product to clinical safety and efficacy.
Bioavailability studies are drug product performance studies used to define
the effect of changes in the physicochemical properties of the drug substance, the formulation of the drug, and the manufacturing process of the drug product.
Quality must be built into the product, it cannot be inspected into it. The Pharmaceutical industries are experiencing a “knowledge and experience deficit” regarding the use of QbD concepts.
MEETING DISSOLUTION REQUIREMENTS PROBLEMS OF VARIABLE CONTROL IN DISSOLUTION ...MukeshKumarBhagat
The dissolution profile data from the pivotal clinical batches and primary (registration) stability batches should be used for the setting of the dissolution acceptance criteria of your product (ie, specification-sampling time point and specification value).
INDIAN REGULATORY REQUIREMENTS FOR LABELING OF COSMETICSPV. Viji
INDIAN REGULATORY REQUIREMENTS FOR LABELING OF COSMETICS , IMPORTANCE OF LABELING , LABELING REQUIREMENTS , Common or generic name of the product. , Product function , Use instruction , Name & address of Manufacturer , Country of manufacture , Manufacture Date , Expiry date , Net Quantity , Retail Sale Price , Storage condition , Barcodes , Batch number , Warning or Caution if hazard exists , Manufacturing License Number , Ingredients , Registration Certificate Number (RCN) , Consumer Care Details , Using Stickers , Brown/Red or green dot , Not a standard pack size under Legal Metrology(Packaged commodities) Rules
Dissolution : Official and Non official methods, Alternative methods of dissolution testing and transport models, Drug release testing, Invitro drug release testing
In this presentation I have mentioned whatever the possible relevant content/guidelines require for biowaiver application.
Citation Is done at the end of slide.
Content is up to date & true to my belief.
Thanks & Best Regards.
Anurag Pandey
B.Pharm (FACULTY OF PHARMACY, INVERTIS UNIVERSITY)
M.Pharm (INSTITUTE OF PHARMACY, NIRMA UNIVERSITY)
Email :- anurag.dmk05@gmail.com
The release of the drug substance from the drug product leading to the bioavailability of the drug substance. The assessment of drug product performance is imp. Since bioavailability is related both to the pharmacodynamic responses and the adverse events. The performance tests relate the quality of a drug product to clinical safety and efficacy.
Bioavailability studies are drug product performance studies used to define
the effect of changes in the physicochemical properties of the drug substance, the formulation of the drug, and the manufacturing process of the drug product.
Quality must be built into the product, it cannot be inspected into it. The Pharmaceutical industries are experiencing a “knowledge and experience deficit” regarding the use of QbD concepts.
MEETING DISSOLUTION REQUIREMENTS PROBLEMS OF VARIABLE CONTROL IN DISSOLUTION ...MukeshKumarBhagat
The dissolution profile data from the pivotal clinical batches and primary (registration) stability batches should be used for the setting of the dissolution acceptance criteria of your product (ie, specification-sampling time point and specification value).
INDIAN REGULATORY REQUIREMENTS FOR LABELING OF COSMETICSPV. Viji
INDIAN REGULATORY REQUIREMENTS FOR LABELING OF COSMETICS , IMPORTANCE OF LABELING , LABELING REQUIREMENTS , Common or generic name of the product. , Product function , Use instruction , Name & address of Manufacturer , Country of manufacture , Manufacture Date , Expiry date , Net Quantity , Retail Sale Price , Storage condition , Barcodes , Batch number , Warning or Caution if hazard exists , Manufacturing License Number , Ingredients , Registration Certificate Number (RCN) , Consumer Care Details , Using Stickers , Brown/Red or green dot , Not a standard pack size under Legal Metrology(Packaged commodities) Rules
Dissolution : Official and Non official methods, Alternative methods of dissolution testing and transport models, Drug release testing, Invitro drug release testing
Quality-by-Design In Pharmaceutical DevelopmentPrabhjot kaur
Quality-by-Design In Pharmaceutical Development: Introduction, ICH Q8 guideline, Regulatory and industry views on QbD, Scientifically based QbD - examples of application. M. Pharmacy 2nd Semester (Computer aided drug delivery system)
Qbd is a technique of planing a safeguard for the formulation from the process of starting material to the final product , its main aim is to built the quality in the product not to testing.
DEFINITION,PRINCIPLE, OBJECTIVES, ELEMENTS AND TOOLS OF QUALITY BY DESIGN (Qb...Durgadevi Ganesan
Quality by Design is a concept first outlined by Joseph M. Juran in various publications. He supposed that quality could be planned. The concept of QBD was mention in ICH Q8 guidelines, which states that, “To identify quality can not be tested in products, i.e. Quality should be built in to product by design.”
What is Quality by Design (QbD)?
Quality by Design (QbD) is a strategic approach employed in various industries, including pharmaceuticals, manufacturing, and product development, to ensure the consistent delivery of high-quality products.
Why QbD?
Principle of QbD
Objectives of QbD
ELEMENTS OF PHARMACEUTICAL QUALITY BY DESIGN:
- Quality Target Product Profile
- Critical Quality Attributes
- Product Design and Understanding
- Process Design and Understanding
- Process Design and Understanding
- Design space
- Control Strategy
- Continual Improvement
DESIGN TOOLS
- Prior Knowledge
- Risk Assessment
- Mechanistic Model, Design of Experiments, and Data Analysis
- Process Analytical Technology
What is ICH Q8 guidelines?
Image result for ICH Pharmaceutical development guideline-Q8
The ICH Q8 guideline is intended to provide guidance on the contents of Section 3.2. P. 2 (Pharmaceutical Development) for drug products as defined in the scope of Module 3 of the Common Technical Document (ICH topic M4).
The Pharmaceutical Quality by Design is a systematic approach to development that begins with predefined objectives and emphasizes product and process understanding and process control based on sound science and quality risk management.
Quality cannot be tested into products; it has to be built in by design.
This is the seminar on Quality By Design (QbD) .
In this will discuss about Concept , Objectives, Benefits, Key Aspects of QbD.
Specially Design for a Seminar type Presentation.
Thank You , Keep reading and keep sharing.
QbD is new concept in pharmaceutical industries which is beneficial for producing and maintaining quality in product. With help of QbD a quality is built in product during manufacturing.
QA Paediatric dentistry department, Hospital Melaka 2020Azreen Aj
QA study - To improve the 6th monthly recall rate post-comprehensive dental treatment under general anaesthesia in paediatric dentistry department, Hospital Melaka
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptxR3 Stem Cell
R3 Stem Cells and Kidney Repair: A New Horizon in Nephrology" explores groundbreaking advancements in the use of R3 stem cells for kidney disease treatment. This insightful piece delves into the potential of these cells to regenerate damaged kidney tissue, offering new hope for patients and reshaping the future of nephrology.
We understand the unique challenges pickleball players face and are committed to helping you stay healthy and active. In this presentation, we’ll explore the three most common pickleball injuries and provide strategies for prevention and treatment.
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfSachin Sharma
This content provides an overview of preventive pediatrics. It defines preventive pediatrics as preventing disease and promoting children's physical, mental, and social well-being to achieve positive health. It discusses antenatal, postnatal, and social preventive pediatrics. It also covers various child health programs like immunization, breastfeeding, ICDS, and the roles of organizations like WHO, UNICEF, and nurses in preventive pediatrics.
Welcome to Secret Tantric, London’s finest VIP Massage agency. Since we first opened our doors, we have provided the ultimate erotic massage experience to innumerable clients, each one searching for the very best sensual massage in London. We come by this reputation honestly with a dynamic team of the city’s most beautiful masseuses.
How many patients does case series should have In comparison to case reports.pdfpubrica101
Pubrica’s team of researchers and writers create scientific and medical research articles, which may be important resources for authors and practitioners. Pubrica medical writers assist you in creating and revising the introduction by alerting the reader to gaps in the chosen study subject. Our professionals understand the order in which the hypothesis topic is followed by the broad subject, the issue, and the backdrop.
https://pubrica.com/academy/case-study-or-series/how-many-patients-does-case-series-should-have-in-comparison-to-case-reports/
Antibiotic Stewardship by Anushri Srivastava.pptxAnushriSrivastav
Stewardship is the act of taking good care of something.
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
WHO launched the Global Antimicrobial Resistance and Use Surveillance System (GLASS) in 2015 to fill knowledge gaps and inform strategies at all levels.
ACCORDING TO apic.org,
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
ACCORDING TO pewtrusts.org,
Antibiotic stewardship refers to efforts in doctors’ offices, hospitals, long term care facilities, and other health care settings to ensure that antibiotics are used only when necessary and appropriate
According to WHO,
Antimicrobial stewardship is a systematic approach to educate and support health care professionals to follow evidence-based guidelines for prescribing and administering antimicrobials
In 1996, John McGowan and Dale Gerding first applied the term antimicrobial stewardship, where they suggested a causal association between antimicrobial agent use and resistance. They also focused on the urgency of large-scale controlled trials of antimicrobial-use regulation employing sophisticated epidemiologic methods, molecular typing, and precise resistance mechanism analysis.
Antimicrobial Stewardship(AMS) refers to the optimal selection, dosing, and duration of antimicrobial treatment resulting in the best clinical outcome with minimal side effects to the patients and minimal impact on subsequent resistance.
According to the 2019 report, in the US, more than 2.8 million antibiotic-resistant infections occur each year, and more than 35000 people die. In addition to this, it also mentioned that 223,900 cases of Clostridoides difficile occurred in 2017, of which 12800 people died. The report did not include viruses or parasites
VISION
Being proactive
Supporting optimal animal and human health
Exploring ways to reduce overall use of antimicrobials
Using the drugs that prevent and treat disease by killing microscopic organisms in a responsible way
GOAL
to prevent the generation and spread of antimicrobial resistance (AMR). Doing so will preserve the effectiveness of these drugs in animals and humans for years to come.
being to preserve human and animal health and the effectiveness of antimicrobial medications.
to implement a multidisciplinary approach in assembling a stewardship team to include an infectious disease physician, a clinical pharmacist with infectious diseases training, infection preventionist, and a close collaboration with the staff in the clinical microbiology laboratory
to prevent antimicrobial overuse, misuse and abuse.
to minimize the developme
Navigating the Health Insurance Market_ Understanding Trends and Options.pdfEnterprise Wired
From navigating policy options to staying informed about industry trends, this comprehensive guide explores everything you need to know about the health insurance market.
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
Struggling with intense fears that disrupt your life? At Renew Life Hypnosis, we offer specialized hypnosis to overcome fear. Phobias are exaggerated fears, often stemming from past traumas or learned behaviors. Hypnotherapy addresses these deep-seated fears by accessing the subconscious mind, helping you change your reactions to phobic triggers. Our expert therapists guide you into a state of deep relaxation, allowing you to transform your responses and reduce anxiety. Experience increased confidence and freedom from phobias with our personalized approach. Ready to live a fear-free life? Visit us at Renew Life Hypnosis..
2. Introduction
Pharmaceutical quality refers to product free of contamination and reproducibly
delivers the therapeutic benefit promised in the label to the consumer. The Quality
of the pharmaceutical product can be evaluated by in vivo or in vitro performance
tests. Quality by design assures in vitro product performance and In vitro product
performance provides assurance of in vivo product performance. “Hence Quality by
design relate to Product Performance”.
Definition : The pharmaceutical Quality by Design (QbD) is a systematic approach
to development that begins with predefined objectives and emphasizes product and
process understanding and process control, based on sound science and quality risk
management. Quality by Design (QbD) is emerging to enhance the assurance of
safe, effective drug supply to the consumer, and also offers promise to significantly
improve manufacturing quality performance.
3. Key characteristics of QbD
• A tool for focused & efficient drug development
• Dynamic and systematic process
• Relies on the concept that Quality can be built in as a continuum
• It is applicable to Drug Product and Drug Substance development (chemicals / biologics)
• It is applicable to analytical methods
• Can implemented partially or totally
• Can be used at any time in the life cycle of the Drug
• Always encouraged by Regulators.
5. Table of contents
1. Introduction
1.1 Objective
1.2 Scope
2. Pharmaceutical Development
2.1 Components of Drug Product
2.1.1 Drug Substance
2.1.2 Excipients
2.2 Drug Product
2.2.1Formulation Development
2.2.2 Overages
2.2.3 Physiochemical and Biological Properties
2.3 Manufacturing Process Development
2.4 Container Closure System
2.5 Microbial Attributes
2.6 Compatibility
6. 1. Introduction : The Pharmaceutical Development section provides an
opportunity to present the knowledge gained through the application of
scientific approaches and quality risk management to the development of a
product and its manufacturing process
Objective : This guideline describes the suggested contents for the 3.2.P.2
(Pharmaceutical Development) section of a regulatory submission in the
ICH M4 Common Technical Document (CTD) format.
Scope : This guideline is intended to provide guidance on the contents of
Section 3.2.P.2 (Pharmaceutical Development) for drug products as defined
in the scope of Module 3 of the Common Technical Document (ICH
guideline M4).
7. 2. Pharmaceutical development : The aim of pharmaceutical
development is to design a quality product and its manufacturing process to
consistently deliver the intended performance of the product.
The information and knowledge gained from pharmaceutical development
studies and manufacturing experience provide scientific understanding to
support the establishment of the design space, specifications, and
manufacturing controls.
9. DRUG SUBSTANCES : “The physicochemical and biological properties of the
drug substance that can influence the performance of the drug product and its
manufacturability.” Examples of physicochemical and biological properties that
might need to be examined include •Solubility, •Water content, •Particle size,
•Crystal properties, •Biological activity, •Permeability.
EXCIPIENTS :
• The excipients chosen, their concentration, and the characteristics that can
influence the drug product performance or manufacturability should be discussed
relative to the respective function of each excipients.
• The compatibility of the drug substance with excipients should be evaluated.
For products that contain more than one drug substance, the compatibility of the
drug substances with each other should also be evaluated.
11. FORMULATION DEVELOPMENT :
• A summary should be provided describing the development of the
formulation, including identification of those attributes that are critical to the
quality of the drug product and also highlight the evolution of the formulation
design from initial concept up to the final design.
• Information from comparative in vitro studies (e.g., dissolution) or
comparative in vivo studies (e.g., BE) that links clinical formulations to the
proposed commercial formulation.
• A successful correlation can assist in the selection of appropriate dissolution
acceptance criteria, and can potentially reduce the need for further
bioequivalence studies following changes to the product or its manufacturing
process.
12. OVERAGES: Overages in the manufacture of the drug product, whether they
appear in the final formulated product or not, should be justified considering the
safety and efficacy of the product. Information should be provided on the
1) Amount of overage,
2) Reason for the overage (e.g., to compensate for expected and documented
manufacturing losses),
3) Justification for the amount of overage.
PHYSIOCHEMICAL & BIOLOGICAL PROPERTIES :
• The physicochemical and biological properties relevant to the safety,
performance or manufacturability of the drug product should be identified and
discussed.
• This includes the physiological implications of drug substance and formulation
attributes.
14. MANUFACTURING PROCESS DEVELOPMENT :
• Important consideration to critical formulation attributes, together with the available
manufacturing process options, in order to address the selection of the manufacturing
process and confirm the appropriateness of the components.
•Appropriateness of the equipment used for the intended products should be discussed.
•The manufacturing process development programme or process improvement
programme should identify any critical process parameters that should be monitored or
controlled (e.g., granulation end point) to ensure that the product is of the desired quality.
CONTAINER CLOSURE SYSTEM :The choice for selection of the container closure
system for the commercial product should be discussed.
• The choice of materials for primary packaging and secondary packaging should be
justified.
• A possible interaction between product and container or label should be considered.
15. MICROBIOLOGICAL ATTRIBUTES : The selection and effectiveness of
preservative systems in products containing antimicrobial preservative or the
antimicrobial effectiveness of products that are inherently antimicrobial.
• For sterile products, the integrity of the container closure system as it relates
to preventing microbial contamination.
• The lowest specified concentration of antimicrobial preservative should be
justified in terms of efficacy and safety, such that the minimum concentration
of preservative that gives the required level of efficacy throughout the intended
shelf life of the product is used.
COMPATIBILITY : The compatibility of the drug product with
reconstitution diluents (e.g., precipitation, stability) should be addressed to
provide appropriate and supportive information for the labeling.
18. Regulatory and industry views on QbD
Future state vision: both industry and regulatory need to change
Regulators Industry
Promote open communication
Reviewers who are accessible, engaged, and
expert Change the content of applications
Encourage knowledge sharing Eliminate
non-value added information .
More science & risk-based evaluation of
applications
Reduce post-approval change regulatory
hurdles
Be open and transparent in sharing
knowledge: success and failure.
Scientists can understand the needs of the
Regulators.
Change the content of applications.
-Share the knowledge.
-Focus on manufacturing sciences.
Move to science-based, risk mitigated
applications
Provide insight into manufacturing sciences
so as to reduce need for post-approval
change
19. Scientifically based QbD - examples of
application.
• Application of QbD for Enhancement of the Solubility and Dissolution of Class II
BCS Drug Using Polymeric Surfactants and Crystallization Inhibitors: Development
of Controlled - Release Tablets
• Application of QbD to Development of Analytical Separation Methods
For chromatographic technique e.g
i. In determination of impurity
ii. In screening of column used for chromatography
iii. In development of HPLC method for drug products/substances
20. For hyphenated techniques e.g.
i. In LC–MS method development
ii. In bioanalytical method development
• Quality-by-Design Based Development of a Self-Micro-emulsifying Drug Delivery
System [SMEDDS] to Reduce Food Effect of Nelfinavir Mesylate
• Quality by Design Approach for Optimizing the Formulation and Physical
Properties of Extemporaneously Prepared Orodispersible Films:
21. Conclusion
• Agencies and Industry are moving from ‘blind’ compliance to ‘science and risk-based’
compliance Industry wants this to be global.
• This evolution is based on process understanding and continuous improvement throughout
the product life cycle Traditional process validation being replaced by a much better
alternative.
- Building in quality.
- Continuous quality verification and improvement.
• Moving from ‘Quality by Testing’ to ‘Quality by Design’ should, in principle, allow
significant regulatory flexibility helps both regulators and industry focus on higher risk or
added value activities.
22. References
• Patwardhan DM, Amrutkar SS, Kotwal TS and Wagh MP: Application of quality by
design to different aspects of pharmaceutical technologies. Int J Pharm Sci Res
2017; 8(9) 3649-62
• Jaiprakash N. Sangshetti Mrinmayee Deshpande Zahid Zaheer Devanand B. Shinde
Rohidas Arote Quality by design approach: Regulatory need Arabian Journal of
Chemistry 2014 Volume 10, S3412-S3425
• ICH HARMONISED TRIPARTITE GUIDELINE: PHARMACEUTICAL
DEVELOPMENT Q8(R2) INTERNATIONAL CONFERENCE ON
HARMONISATION OF TECHNICAL REQUIREMENTS FOR
REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE. 2009